Alzheimer’s (AriBio)

Enrolling Now
Study Information

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease.

Apply to Participate

If you are interested in participating in this study, please complete the following preliminary qualification form.

We will follow-up with you after we have received your submission.

"*" indicates required fields

General Information

Name*
ZIP / Postal Code*

Preferences

Email Opt-In*
SMS/Text Opt-In*
This field is for validation purposes and should be left unchanged.